Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Avoid These 3 Biotech Stocks That Were Recently Downgraded

The biotech industry is making considerable progress in developing viable drugs and therapies for treating several critical diseases with the integration of advanced technologies. But although rising investments...

GMAB : 43.12 (+1.99%)
ARGX : 331.67 (+2.50%)
XOMA : 25.66 (+5.60%)
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 331.67 (+2.50%)
ALPMF : 17.2500 (+0.88%)
AVDL : 7.95 (-0.38%)
BAX : 83.61 (+0.47%)
GSK : 38.93 (-0.46%)
GRFS : 15.39 (+6.51%)
MTZPY : 18.6000 (-0.13%)
NVS : 83.48 (-1.07%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

BIIB : 300.19 (+0.17%)
JNJ : 164.75 (-0.28%)
ALXN : 182.50 (+1.70%)
INCY : 75.99 (+1.27%)
BLUE : 18.32 (+3.62%)
ARGX : 331.67 (+2.50%)
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate....

JNJ : 164.75 (-0.28%)
RHHBY : 46.0700 (-1.60%)
ABBV : 107.73 (-0.32%)
ARGX : 331.67 (+2.50%)
argenx SE to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2021 / argenx SE (NASDAQ:ARGX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 14, 2021 at 8:30 AM Eastern Time....

ARGX : 331.67 (+2.50%)
Myasthenia Gravis Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The report for Myasthenia Gravis Treatment offers an assiduous analysis of contemporary market trends, driving factors, consumer behavior, key player strategies, product usage and brand positioning. The...

ARGX : 331.67 (+2.50%)
ALPMF : 17.2500 (+0.88%)
AVDL : 7.95 (-0.38%)
BAX : 83.61 (+0.47%)
GSK : 38.93 (-0.46%)
GRFS : 15.39 (+6.51%)
MTZPY : 18.6000 (-0.13%)
NVS : 83.48 (-1.07%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
argenx SE to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / argenx SE (NASDAQ:ARGX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 2:30 PM Eastern Time....

ARGX : 331.67 (+2.50%)
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

and GHENT, , /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced...

ARGX : 331.67 (+2.50%)
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

JNJ : 164.75 (-0.28%)
RHHBY : 46.0700 (-1.60%)
HALO : 42.04 (-0.02%)
ARGX : 331.67 (+2.50%)
argenx SE to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 22, 2020 / argenx SE (NASDAQ:ARGX) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on October 22, 2020 at 2:30 PM Eastern...

ARGX : 331.67 (+2.50%)

Barchart Exclusives

US Stock Markets: Stop the Seasonal Madness
A popular theme on financial television these days is September is a seasonally bearish time for US stock markets. The evidence does not support this idea. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar